Wealth Alliance Sells 2,298 Shares of Genmab A/S (NASDAQ:GMAB)

Wealth Alliance decreased its position in Genmab A/S (NASDAQ:GMAB) by 21.5% during the 4th quarter, Holdings Channel reports. The firm owned 8,403 shares of the company’s stock after selling 2,298 shares during the quarter. Wealth Alliance’s holdings in Genmab A/S were worth $268,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the company. Alliancebernstein L.P. grew its holdings in shares of Genmab A/S by 21.0% in the 2nd quarter. Alliancebernstein L.P. now owns 8,187,576 shares of the company’s stock worth $311,210,000 after purchasing an additional 1,420,915 shares during the last quarter. BlackRock Inc. grew its holdings in shares of Genmab A/S by 1.6% in the 1st quarter. BlackRock Inc. now owns 5,494,689 shares of the company’s stock worth $198,799,000 after purchasing an additional 86,571 shares during the last quarter. Capital International Investors grew its holdings in Genmab A/S by 7.7% during the 1st quarter. Capital International Investors now owns 3,952,446 shares of the company’s stock worth $145,433,000 after acquiring an additional 283,031 shares during the last quarter. Macquarie Group Ltd. grew its holdings in Genmab A/S by 11.1% during the 1st quarter. Macquarie Group Ltd. now owns 3,484,632 shares of the company’s stock worth $131,580,000 after acquiring an additional 347,437 shares during the last quarter. Finally, Wellington Management Group LLP grew its holdings in Genmab A/S by 5.8% during the 1st quarter. Wellington Management Group LLP now owns 3,333,824 shares of the company’s stock worth $120,618,000 after acquiring an additional 183,578 shares during the last quarter. Institutional investors own 7.07% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have commented on GMAB. Citigroup lowered shares of Genmab A/S from a “neutral” rating to a “sell” rating in a report on Monday, January 22nd. Truist Financial reissued a “buy” rating and set a $50.00 price objective on shares of Genmab A/S in a report on Tuesday, March 26th. HC Wainwright reissued a “buy” rating and set a $50.00 price objective on shares of Genmab A/S in a report on Thursday, April 4th. BMO Capital Markets raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating and increased their price objective for the stock from $46.00 to $48.00 in a report on Friday, February 23rd. Finally, Morgan Stanley reissued an “underweight” rating on shares of Genmab A/S in a report on Tuesday, March 26th. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $48.50.

Genmab A/S Trading Down 0.7 %

Genmab A/S stock opened at $28.33 on Friday. Genmab A/S has a 1 year low of $26.32 and a 1 year high of $42.72. The company has a market cap of $18.73 billion, a PE ratio of 29.51, a PEG ratio of 2.05 and a beta of 0.99. The company’s 50-day moving average is $29.36 and its two-hundred day moving average is $30.34.

Genmab A/S (NASDAQ:GMAB) last released its earnings results on Wednesday, February 14th. The company reported $0.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.34 by $0.02. The company had revenue of $675.29 million for the quarter, compared to the consensus estimate of $678.14 million. Genmab A/S had a net margin of 26.50% and a return on equity of 18.06%. Research analysts forecast that Genmab A/S will post 1.06 EPS for the current year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.